Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, Hirayama M, Takahashi A
Department of Neurology, Nagoya Daini Red Cross Hospital, Japan.
J Auton Nerv Syst. 1994 Sep;49(1):81-4. doi: 10.1016/0165-1838(94)90023-x.
Cardiac scintigraphy with meta-[123I]iodobenzylguanidine (MIBG) is used to assess cardiac sympathetic function. We performed [123I]MIBG scintigraphy in 7 patients with neurological diseases presenting orthostatic hypotension and other autonomic failures (AF), 22 neurological patients without AF, and 9 healthy subjects. Thallium scintigraphy and echocardiography were also performed in all subjects. In this series, patients with any evidence of cardiac dysfunction were excluded. No [123I]MIBG accumulation was observed in all patients with AF, and cardiac defects were noted in 7 patients (5 with Parkinson's disease [PD], 2 with spinocerebellar degenerations [SCD]), and in some patients without AF. In contrast, the distribution of [123I]MIBG was normal in all the healthy subjects. No decrease in [123I]MIBG accumulation was resulted from drug therapy (droxidopa, amezinium and thyrotropin-releasing hormone). In conclusion, reduced accumulation on [123I]MIBG scintigraphy may be due to myocardial beta-adrenoceptor dysfunction or reduced central sympathetic activity of the heart, or both.
使用间位 - [123I] 碘苄胍（MIBG）进行心脏闪烁扫描术来评估心脏交感神经功能。我们对7例患有神经系统疾病且出现体位性低血压和其他自主神经功能衰竭（AF）的患者、22例无AF的神经系统疾病患者以及9名健康受试者进行了[123I]MIBG闪烁扫描术。所有受试者还进行了铊闪烁扫描术和超声心动图检查。在该系列研究中，排除了任何有心脏功能障碍证据的患者。所有AF患者均未观察到[123I]MIBG摄取，7例患者（5例帕金森病[PD]、2例脊髓小脑变性[SCD]）以及一些无AF的患者出现了心脏缺损。相比之下，所有健康受试者的[123I]MIBG分布均正常。药物治疗（屈昔多巴、甲磺酸阿米三嗪和促甲状腺激素释放激素）未导致[123I]MIBG摄取减少。总之，[123I]MIBG闪烁扫描术摄取减少可能是由于心肌β - 肾上腺素能受体功能障碍或心脏中枢交感神经活动降低，或两者皆有。
